×
Request Free Sample ×
Prostate Cancer Market Therapeutics Research Report - Forecast till 2035 Infographic

Kindly complete the form below to receive a free sample of this Report

* Please use a valid business email

Leading companies partner with us for data-driven Insights

clients tt-cursor
Hero Background

Prostate Cancer Market

ID: MRFR/Pharma/1051-CR
78 Pages
Kinjoll Dey
January 2020

Prostate Cancer Market Research Report Information by Type (Prostate Adenocarcinoma, Small Cell Carcinoma), By Component (Therapy and Diagnosis), By End-User (Specialty Centers, Hospital & Clinics), and By Region (North America, Europe, Asia-Pacific, And Rest of The World) – Therapeutics Industry Forecast Till 2035

Share:
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Prostate cancer Market Infographic
Purchase Options
Compare License
Summary Table of Contents Segmentation Download PDF

Prostate Cancer Market Summary

As per Market Research Future analysis, the Prostate cancer Market Size was estimated at 7.35 USD Billion in 2024. The Prostate cancer industry Therapeutics is projected to grow from 7.91 USD Billion in 2025 to 16.5 USD Billion by 2035, exhibiting a compound annual growth rate (CAGR) of 7.62% during the forecast period 2025 - 2035.

Key Market Trends & Highlights

The Prostate cancer Market is experiencing transformative growth driven by technological advancements and increasing patient-centric approaches.

  • Advancements in diagnostic technologies are enhancing early detection and treatment outcomes in the Prostate cancer Market.
  • The rise of personalized medicine is reshaping treatment protocols, particularly in North America, the largest market.
  • In Asia-Pacific, there is a notable increase in patient education and advocacy, contributing to better awareness and screening initiatives.
  • The growing incidence of prostate cancer and rising awareness are key drivers propelling market expansion, particularly in biopsy and surgery segments.

Market Size & Forecast

2024 Market Size 7.35 (USD Billion)
2035 Market Size 16.5 (USD Billion)
CAGR (2025 - 2035) 7.62%

Major Players

AbbVie (US), Bristol-Myers Squibb (US), Johnson & Johnson (US), Astellas Pharma (JP), Merck & Co. (US), Pfizer (US), Novartis (CH), Sanofi (FR), Amgen (US), GSK (GB)

Prostate Cancer Market Trends

The Prostate cancer Market is currently experiencing a dynamic evolution, driven by advancements in diagnostic technologies and treatment modalities. The increasing prevalence of prostate cancer globally has prompted a surge in research and development efforts aimed at improving patient outcomes. Innovative therapies, including targeted treatments and immunotherapies, are gaining traction, suggesting a shift towards more personalized approaches in managing this disease. Furthermore, the integration of artificial intelligence in diagnostic processes appears to enhance early detection rates, potentially leading to better prognoses for patients. In addition to technological advancements, the Prostate cancer Market is influenced by changing demographics and heightened awareness surrounding men's health issues. Educational campaigns and advocacy initiatives are likely contributing to increased screening rates, which may facilitate earlier intervention and treatment. As healthcare systems adapt to these trends, the market landscape is expected to evolve, with a focus on accessibility and affordability of care. Overall, the Prostate cancer Market seems poised for continued growth, reflecting a commitment to improving the quality of life for those affected by this condition.

Advancements in Diagnostic Technologies

The Prostate cancer Market is witnessing a notable shift due to the emergence of advanced diagnostic tools. Techniques such as multiparametric MRI and liquid biopsies are enhancing the accuracy of early detection, which may lead to timely interventions. These innovations are likely to change the standard of care, as they provide clinicians with more precise information regarding tumor characteristics.

Rise of Personalized Medicine

There is a growing trend towards personalized medicine within the Prostate cancer Market. Tailored treatment plans based on genetic profiling and biomarker analysis are becoming more prevalent. This approach appears to improve treatment efficacy and minimize adverse effects, as therapies are increasingly aligned with individual patient needs.

Increased Focus on Patient Education and Advocacy

The Prostate cancer Market is also seeing a heightened emphasis on patient education and advocacy. Initiatives aimed at raising awareness about prostate health are likely contributing to increased screening and early detection. This trend suggests a shift towards proactive management of the disease, empowering patients to take charge of their health.

Prostate Cancer Market Drivers

Rising Incidence of Prostate Cancer

The Global Prostate Cancer Market Industry is experiencing growth due to the increasing incidence of prostate cancer worldwide. According to credible health statistics, prostate cancer is one of the most common cancers among men, with millions diagnosed annually. This rising prevalence is driving demand for innovative treatment options and diagnostic tools. As awareness increases, more men are seeking screening and treatment, contributing to the market's expansion. The projected market value of 7.35 USD Billion in 2024 underscores the urgency for effective solutions in managing this disease.

Market Segment Insights

By Diagnosis Method: Biopsy (Largest) vs. Blood Test (Fastest-Growing)

In the Prostate Cancer Market, the diagnosis methods are primarily divided into four categories: Biopsy, Imaging, Blood Test, and Digital Rectal Examination (DRE). Biopsy holds the largest market share, as it is considered the gold standard for diagnosing prostate cancer. It is followed by Imaging techniques, which play a significant role in visualizing cancerous areas. Blood Tests, particularly prostate-specific antigen (PSA) tests, are gaining traction, while DRE remains a traditional yet less commonly used method in the diagnosis process.

Biopsy (Dominant) vs. Blood Test (Emerging)

Biopsy remains the dominant diagnosis method for prostate cancer, as it provides definitive evidence of cancer presence through tissue sampling. The procedure's reliability and accuracy make it the most preferred option among clinicians. On the other hand, Blood Tests, especially PSA testing, are emerging as a favorable alternative due to their non-invasive nature and ease of administration. This trend is driven by advancements in blood test technologies and the growing preference for less invasive diagnostic methods, making Blood Tests an increasingly viable option for initial screenings and monitoring.

By Treatment Type: Surgery (Largest) vs. Hormone Therapy (Fastest-Growing)

In the prostate cancer market, treatment options are diverse, with Surgical interventions dominating the segment due to their established effectiveness in tumor removal. Following closely are Radiation Therapy and Hormone Therapy, both playing pivotal roles in the treatment regimen based on disease progression and patient-specific factors. Chemotherapy, while important for certain advanced cases, holds a smaller share compared to the others, illustrating the preference for targeted and minimally invasive options.

Surgery (Dominant) vs. Hormone Therapy (Emerging)

Surgery remains the dominant treatment approach for prostate cancer, providing immediate results and a significant potential for cure, especially in early-stage diagnoses. This option encompasses procedures like radical prostatectomy, which have seen refinements in technique and technology, enhancing recovery times and outcomes. In contrast, Hormone Therapy is gaining momentum as an emerging treatment thanks to its effectiveness in managing advanced prostate cancer and metastasis. This rise is driven by an increasing understanding of androgen deprivation therapy, making it a critical component in personalized treatment plans. As research continues, Hormone Therapy is becoming an essential part of integrated approaches for disease management.

By Stage of Cancer: Localized (Largest) vs. Metastatic (Fastest-Growing)

In the prostate cancer market, the largest segment is 'Localized', which captures a significant share of the patient population diagnosed at earlier stages. This segment is characterized by its higher accessibility to treatment options, leading to favorable outcomes. Following closely are the 'Locally Advanced' and 'Metastatic' stages, with the latter representing a smaller portion of the market but experiencing increased diagnosis rates due to enhanced screening methods and awareness campaigns. As more patients are being diagnosed at later stages, this has implications on treatment modalities and market strategies. Growth trends indicate that the 'Metastatic' stage is the fastest-growing segment in the prostate cancer market. This growth can be attributed to advancements in targeted therapies and an increasing number of clinical trials focused on patients with metastatic prostate cancer. Moreover, the rising prevalence of prostate cancer in older demographics is driving demand for innovative treatments, leading to a shift in market focus toward late-stage therapies. As a result, pharmaceutical companies are increasingly investing in research and development to address the unmet needs of metastatic patients.

Localized (Dominant) vs. Locally Advanced (Emerging)

The 'Localized' stage of prostate cancer represents the dominant segment in the market, comprising patients with tumors that are confined within the prostate gland. This stage typically involves lower mortality rates and presents a wide range of treatment options, including surgery and radiation therapy, contributing to a favorable outlook for patients. In contrast, the 'Locally Advanced' stage, which signifies a progression beyond the prostate but still confined to the surrounding area, is an emerging segment. Patients in this stage may require a combination of treatments and are often part of clinical trials exploring new therapeutic options. The dynamics in these segments reflect the complexity of disease management and the ongoing advancements in personalized medicine.

By Patient Demographics: Age Group (Largest) vs. Ethnicity (Fastest-Growing)

In the prostate cancer market, the patient demographics segment highlights the significant share of various age groups, with men aged 65 and older making up the largest portion of diagnosed cases. This demographic accounts for a major chunk of the market, significantly influencing treatment decisions and healthcare strategies. In terms of ethnicity, there is a notable representation of African American men, who experience higher incidence rates of prostate cancer compared to other ethnic groups, prompting targeted healthcare initiatives and support systems.

Age Group: 65+ (Dominant) vs. Ethnicity: African American (Emerging)

The age group of 65 years and older represents a dominant segment in the prostate cancer market due to the increased risk of prostate cancer with advancing age, driving a greater need for screening and treatment options tailored to older patients. On the other hand, the emerging concern of the African American demographic highlights an urgent need, as this group shows not only a higher prevalence of prostate cancer but also unique biological and socio-economic factors that contribute to their risk. This ethnic group is increasingly becoming a focus for targeted therapies, educational campaigns, and community health programs, reflecting a shift in understanding the nuances within patient demographics.

By Healthcare Setting: Hospital (Largest) vs. Outpatient Clinic (Fastest-Growing)

In the prostate cancer market, healthcare settings play a crucial role in treatment delivery. Hospitals currently dominate this segment due to their comprehensive resources and specialist availability, capturing a significant market share. Outpatient clinics are gaining traction, driven by the increasing preference for cost-effective treatment options and improved patient convenience, thereby reshaping the traditional treatment landscape.

Hospital: (Dominant) vs. Outpatient Clinic (Emerging)

Hospitals dominate the prostate cancer treatment landscape due to their extensive medical facilities, experienced oncologists, and advanced technology. They provide a range of services, including surgery, chemotherapy, and radiotherapy, fostering a comprehensive treatment environment. In contrast, outpatient clinics are emerging as popular alternatives, focusing on accessibility and convenience. With advancements in ambulatory surgery and telemedicine, outpatient clinics can offer targeted therapies and monitoring, appealing to patients seeking less invasive and more flexible treatment options. This shift reflects a broader trend towards personalized care and efficiency in healthcare delivery.

Get more detailed insights about Prostate Cancer Market
Request Free Sample

Regional Insights

North America : Market Leader in Innovation

North America is poised to maintain its leadership in the prostate cancer market, holding a significant share of 3.5 billion in 2025. The region benefits from advanced healthcare infrastructure, high R&D investments, and a growing aging population, which drives demand for innovative therapies. Regulatory support, including expedited approval processes for new treatments, further catalyzes market growth, ensuring timely access to cutting-edge therapies for patients. The competitive landscape in North America is robust, featuring key players such as AbbVie, Johnson & Johnson, and Merck & Co. These companies are at the forefront of developing novel therapies, including immunotherapies and targeted treatments. The U.S. remains the largest market, with Canada also contributing significantly. The presence of leading pharmaceutical firms fosters a dynamic environment for collaboration and innovation, enhancing treatment options for prostate cancer patients.

Europe : Emerging Market with Growth Potential

Europe's prostate cancer market is projected to reach 2.0 billion by 2025, driven by increasing awareness and early detection initiatives. The region benefits from a strong regulatory framework that encourages the development of new therapies. Countries like Germany and the UK are leading in market growth, supported by government health programs aimed at improving cancer care. The rising prevalence of prostate cancer among aging populations is also a significant demand driver, prompting investments in research and treatment options. The competitive landscape in Europe features major players such as Astellas Pharma and Novartis, who are actively involved in clinical trials and product launches. The presence of a diverse range of treatment options, including hormone therapies and novel agents, enhances patient access to effective care. Collaborative efforts among European nations to standardize treatment protocols further strengthen the market, ensuring that patients receive optimal care across borders.

Asia-Pacific : Rapidly Growing Market Segment

The Asia-Pacific region is witnessing a significant increase in the prostate cancer market, projected to reach 1.5 billion by 2025. Factors contributing to this growth include rising awareness about prostate health, improved diagnostic capabilities, and increasing healthcare expenditure. Countries like Japan and Australia are leading the charge, with government initiatives aimed at enhancing cancer screening and treatment accessibility. The growing aging population in these countries further fuels demand for effective prostate cancer therapies. The competitive landscape in Asia-Pacific is evolving, with both local and international players like Pfizer and GSK making strides in the market. The region is characterized by a mix of traditional and modern treatment approaches, with a focus on integrating innovative therapies. Collaborative research efforts and partnerships between governments and pharmaceutical companies are essential for advancing treatment options and improving patient outcomes in prostate cancer care.

Middle East and Africa : Emerging Market with Challenges

The Middle East and Africa region is gradually developing its prostate cancer market, projected to reach 0.35 billion by 2025. The growth is driven by increasing awareness of prostate cancer and the need for improved healthcare infrastructure. However, challenges such as limited access to advanced treatments and disparities in healthcare quality persist. Government initiatives aimed at enhancing cancer care and early detection are crucial for driving market growth in this region. Countries like South Africa and the UAE are taking steps to improve cancer care, with investments in healthcare facilities and training for medical professionals. The presence of key players, although limited, is growing, with companies like Sanofi and Amgen exploring opportunities in this emerging market. Collaborative efforts between governments and private sectors are essential to address the challenges and enhance treatment options for prostate cancer patients in the region.

Key Players and Competitive Insights

The Prostate cancer Market is characterized by a dynamic competitive landscape, driven by increasing incidence rates and advancements in treatment modalities. Key players such as AbbVie (US), Merck & Co. (US), and Johnson & Johnson (US) are strategically positioned to leverage innovation and partnerships to enhance their market presence. AbbVie (US) focuses on expanding its oncology portfolio through strategic acquisitions and collaborations, while Merck & Co. (US) emphasizes research and development to introduce novel therapies. Johnson & Johnson (US) adopts a multifaceted approach, integrating digital health solutions into its treatment offerings, thereby enhancing patient engagement and outcomes. Collectively, these strategies contribute to a competitive environment that is increasingly centered around innovation and patient-centric solutions.

In terms of business tactics, companies are localizing manufacturing and optimizing supply chains to enhance efficiency and reduce costs. The market structure appears moderately fragmented, with several players vying for market share. However, the influence of major companies is substantial, as they set trends in research, development, and marketing strategies that smaller firms often follow. This competitive structure fosters an environment where innovation is paramount, and companies are compelled to differentiate themselves through unique offerings and operational efficiencies.

In November 2025, AbbVie (US) announced a strategic partnership with a leading biotechnology firm to co-develop a new class of immunotherapies for prostate cancer. This collaboration is expected to accelerate the development timeline and enhance the therapeutic options available to patients, reflecting AbbVie's commitment to innovation in oncology. The partnership not only strengthens AbbVie's pipeline but also positions it favorably against competitors by expanding its therapeutic reach.

In October 2025, Merck & Co. (US) launched a new clinical trial for a combination therapy targeting advanced prostate cancer, which integrates its existing drug portfolio with emerging therapies. This initiative underscores Merck's focus on personalized medicine and its intent to address unmet medical needs in the prostate cancer space. The trial's outcomes could potentially reshape treatment protocols and solidify Merck's leadership in the market.

In September 2025, Johnson & Johnson (US) unveiled a digital health platform designed to support prostate cancer patients throughout their treatment journey. This platform aims to enhance patient adherence and provide real-time data to healthcare providers. By integrating technology into its offerings, Johnson & Johnson (US) is likely to improve patient outcomes and satisfaction, thereby reinforcing its competitive edge in a market that increasingly values digital solutions.

As of December 2025, current trends in the Prostate cancer Market indicate a shift towards digitalization, sustainability, and the integration of artificial intelligence (AI) in treatment protocols. Strategic alliances are becoming more prevalent, as companies recognize the value of collaboration in driving innovation. The competitive differentiation is expected to evolve, moving away from price-based competition towards a focus on technological advancements, innovative therapies, and reliable supply chains. This shift suggests that companies that prioritize research and development, alongside strategic partnerships, will likely emerge as leaders in the evolving landscape.

Key Companies in the Prostate Cancer Market market include

Industry Developments

MDxHealth SA announced a partnership with Oxford University, whose aim is to study the relationship between Genomic Prostate Score (GPS) and test results post-treatment progression of this disease in men who have undergone various forms of localized prostate cancer therapy.

August 2023:

The U.S. Food and Drug Administration (FDA) granted approval to FoundationOneCDx as a companion diagnostic of AKEEGA (abiraterone acetate Dual Action Tablet + niraparib) developed by Janssen Pharmaceuticals. This approval applies specifically to individuals with BRCA-positive metastatic castration-resistant prostate cancer.

July 2023:

A new biomarker test that identified prostate cancer using subspecialty pathology business was introduced by Quest Diagnostic called AmeriPath. The company signed a deal with Envision Sciences Pty Ltd., an Australian clinical diagnostics firm.

April 2022: 

As a part of the Milton and Carroll Petrie Department of Urology at Mount Sinai, a Mount Sinai Robert F. Smith Mobile Prostate Cancer Screening Unit was launched to address the disparity in prostate cancer outcomes for Black men and increase access to care.

March 2022: 

The approval of Pluvicto by the US FDA will allow Novartis to offer a new treatment option for adult patients with prostate-specific membrane antigen-positive metastatic castration-resistant prostate cancer, a variety of advanced prostate cancer.

March 2022:

Merck announced that they would be conducting a Keytruda plus Lynparza clinical trial targeting patients with metastatic-refractory prostate cancers that have keylynk-010.

Future Outlook

Prostate Cancer Market Future Outlook

The Prostate cancer Market is projected to grow at a 7.62% CAGR from 2024 to 2035, driven by advancements in diagnostics, treatment options, and increasing awareness.

New opportunities lie in:

  • Development of personalized immunotherapy treatments for advanced prostate cancer patients.
  • Expansion of telehealth services for remote patient monitoring and consultations.
  • Investment in AI-driven diagnostic tools to enhance early detection rates.

By 2035, the Prostate cancer Market is expected to be robust, reflecting significant advancements and increased patient access.

Market Segmentation

Prostate cancer Market Treatment Type Outlook

  • Surgery
  • Radiation Therapy
  • Hormone Therapy
  • Chemotherapy

Prostate cancer Market Stage of Cancer Outlook

  • Localized
  • Locally Advanced
  • Metastatic

Prostate cancer Market Diagnosis Method Outlook

  • Biopsy
  • Imaging
  • Blood Test
  • Digital Rectal Examination

Prostate cancer Market Healthcare Setting Outlook

  • Hospital
  • Outpatient Clinic
  • Home Care

Prostate cancer Market Patient Demographics Outlook

  • Age Group
  • Ethnicity
  • Socioeconomic Status

Report Scope

MARKET SIZE 2024 7.35(USD Billion)
MARKET SIZE 2025 7.91(USD Billion)
MARKET SIZE 2035 16.5(USD Billion)
COMPOUND ANNUAL GROWTH RATE (CAGR) 7.62% (2024 - 2035)
REPORT COVERAGE Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
BASE YEAR 2024
Market Forecast Period 2025 - 2035
Historical Data 2019 - 2024
Market Forecast Units USD Billion
Key Companies Profiled AbbVie (US), Bristol-Myers Squibb (US), Johnson & Johnson (US), Astellas Pharma (JP), Merck & Co. (US), Pfizer (US), Novartis (CH), Sanofi (FR), Amgen (US), GSK (GB)
Segments Covered Diagnosis Method, Treatment Type, Stage of Cancer, Patient Demographics, Healthcare Setting
Key Market Opportunities Advancements in precision medicine and biomarker discovery enhance treatment options in the Prostate cancer Market.
Key Market Dynamics Rising demand for innovative therapies drives competition and regulatory scrutiny in the prostate cancer treatment landscape.
Countries Covered North America, Europe, APAC, South America, MEA

Market Highlights

Author
Kinjoll Dey
Research Analyst Level I

He is an extremely curious individual currently working in Healthcare and Medical Devices Domain. Kinjoll is comfortably versed in data centric research backed by healthcare educational background. He leverages extensive data mining and analytics tools such as Primary and Secondary Research, Statistical Analysis, Machine Learning, Data Modelling. His key role also involves Technical Sales Support, Client Interaction and Project management within the Healthcare team. Lastly, he showcases extensive affinity towards learning new skills and remain fascinated in implementing them.

Get In Touch

Leave a Comment

FAQs

What is the projected growth of the Prostate Cancer Diagnosis and Therapy market?

The Prostate Cancer Diagnosis and Therapy market is the expected increase in total market value of 16.5 USD billion over a defined forecast period 2025–2035. It is driven by factors such as demand trends, technological advances, regulatory changes, and geographic expansion.

What is the size of the Prostate Cancer Diagnosis and Therapy market?

Prostate Cancer Diagnosis and Therapy market size was valued at approximately 7.35 billion USD in 2024. This figure will reach 16.5 billion USD covering all regions (America, Europe, Asia, MEA and ROW), focusing its segments / services / distribution channels till 2035.

What is the CAGR of the Prostate Cancer Diagnosis and Therapy market?

Prostate Cancer Diagnosis and Therapy market is expected to grow at a CAGR of 7.62% between 2025 and 2035.

How much will the Prostate Cancer Diagnosis and Therapy market be worth by 2035?

Prostate Cancer Diagnosis and Therapy market is expected to be worth of 16.5 billion USD, reflecting growth driven by usage, technology and global demands by the end of 2035.

How will the Prostate Cancer Diagnosis and Therapy market perform over the next 10 years?

Over the next 10 years the Prostate Cancer Diagnosis and Therapy market is expected to shift from usd billion 7.35 to 16.5 billion USD, led by adoption of advanced tech, demographic trends, regulatory approvals, with potential headwinds from 2025 to 2035.

Which region held the largest market share in the prostate cancer diagnosis and therapy market?

North America had the largest share in the market

Who are the key players in the prostate cancer diagnosis and therapy market?

The key players in the market are Abbvie Inc., AstraZeneca, Bayer AG, Sanofi, IpsenPharma.

Download Free Sample

Kindly complete the form below to receive a free sample of this Report

Customer Stories
Case Study
Aerospace & Defense
Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035

Compare Licence

×
Features License Type
Single User Multiuser License Enterprise User
Price $4,950 $5,950 $7,250
Maximum User Access Limit 1 User Upto 10 Users Unrestricted Access Throughout the Organization
Free Customization ✓ ✓ ✓
Direct Access to Analyst ✓ ✓ ✓
Deliverable Format ✓ ✓ ✓
Platform Access ✗ ✗ ✓
Discount on Next Purchase 10% 15% 15%
Printable Versions ✗ ✗ ✓